Computational  ||| S:0 E:14 ||| JJ
identification  ||| S:14 E:29 ||| NN
and  ||| S:29 E:33 ||| CC
experimental  ||| S:33 E:46 ||| JJ
validation  ||| S:46 E:57 ||| NN
of  ||| S:57 E:60 ||| IN
PPRE  ||| S:60 E:65 ||| NNP
motifs  ||| S:65 E:72 ||| NNS
in  ||| S:72 E:75 ||| IN
NHE1  ||| S:75 E:80 ||| NNP
and  ||| S:80 E:84 ||| CC
MnSOD  ||| S:84 E:90 ||| JJ
genes  ||| S:90 E:96 ||| NNS
of  ||| S:96 E:99 ||| IN
human  ||| S:99 E:105 ||| JJ
Activation  ||| S:105 E:116 ||| NNS
of  ||| S:116 E:119 ||| IN
PPARs  ||| S:119 E:125 ||| NNP
has  ||| S:125 E:129 ||| VBZ
been  ||| S:129 E:134 ||| VBN
reported  ||| S:134 E:143 ||| VBN
to  ||| S:143 E:146 ||| TO
inhibit  ||| S:146 E:154 ||| VB
the  ||| S:154 E:158 ||| DT
proliferation  ||| S:158 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
malignant  ||| S:175 E:185 ||| JJ
cells  ||| S:185 E:191 ||| NNS
from  ||| S:191 E:196 ||| IN
different  ||| S:196 E:206 ||| JJ
lineages ||| S:206 E:214 ||| NN
.  ||| S:214 E:216 ||| .
They  ||| S:216 E:221 ||| PRP
are  ||| S:221 E:225 ||| VBP
involved  ||| S:225 E:234 ||| VBN
in  ||| S:234 E:237 ||| IN
transcription  ||| S:237 E:251 ||| JJ
regulation  ||| S:251 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
genes  ||| S:265 E:271 ||| NNS
upon  ||| S:271 E:276 ||| IN
activation  ||| S:276 E:287 ||| NN
by  ||| S:287 E:290 ||| IN
a  ||| S:290 E:292 ||| DT
ligand ||| S:292 E:298 ||| NN
.  ||| S:298 E:300 ||| .
The  ||| S:300 E:304 ||| DT
binding  ||| S:304 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
PPARs  ||| S:315 E:321 ||| JJ
to  ||| S:321 E:324 ||| TO
the  ||| S:324 E:328 ||| DT
promoter  ||| S:328 E:337 ||| NN
sequence  ||| S:337 E:346 ||| NN
either  ||| S:346 E:353 ||| CC
represses  ||| S:353 E:363 ||| NNS
or  ||| S:363 E:366 ||| CC
activates  ||| S:366 E:376 ||| VBG
the  ||| S:376 E:380 ||| DT
gene ||| S:380 E:384 ||| NN
.  ||| S:384 E:386 ||| .
Hence ||| S:386 E:391 ||| RB
,  ||| S:391 E:393 ||| ,
PPARs  ||| S:393 E:399 ||| NNS
represent  ||| S:399 E:409 ||| VBP
promising  ||| S:409 E:419 ||| VBG
targets  ||| S:419 E:427 ||| NNS
for  ||| S:427 E:431 ||| IN
cancer  ||| S:431 E:438 ||| NN
treatment  ||| S:438 E:448 ||| NN
because  ||| S:448 E:456 ||| IN
of  ||| S:456 E:459 ||| IN
their  ||| S:459 E:465 ||| PRP$
anti-proliferative  ||| S:465 E:484 ||| JJ
and  ||| S:484 E:488 ||| CC
pro-apoptotic  ||| S:488 E:502 ||| JJ
activities ||| S:502 E:512 ||| NNS
.  ||| S:512 E:514 ||| .
Here  ||| S:514 E:519 ||| RB
we  ||| S:519 E:522 ||| PRP
computationally  ||| S:522 E:538 ||| VBP
identified  ||| S:538 E:549 ||| VBN
PPAR  ||| S:549 E:554 ||| NNP
binding  ||| S:554 E:562 ||| JJ
regions  ||| S:562 E:570 ||| NNS
in  ||| S:570 E:573 ||| IN
NHE1  ||| S:573 E:578 ||| NNP
and  ||| S:578 E:582 ||| CC
MnSOD ||| S:582 E:587 ||| JJ
.  ||| S:587 E:589 ||| .
We  ||| S:589 E:592 ||| PRP
further  ||| S:592 E:600 ||| RB
validated  ||| S:600 E:610 ||| VB
the  ||| S:610 E:614 ||| DT
predictions  ||| S:614 E:626 ||| NNS
in  ||| S:626 E:629 ||| IN
vitro ||| S:629 E:634 ||| NN
.  ||| S:634 E:636 ||| .
Our  ||| S:636 E:640 ||| PRP$
results  ||| S:640 E:648 ||| NNS
computationally  ||| S:648 E:664 ||| VBP
predicted  ||| S:664 E:674 ||| VBN
the  ||| S:674 E:678 ||| DT
presence  ||| S:678 E:687 ||| NN
of  ||| S:687 E:690 ||| IN
2  ||| S:690 E:692 ||| CD
PPRE  ||| S:692 E:697 ||| NN
motifs  ||| S:697 E:704 ||| NNS
in  ||| S:704 E:707 ||| IN
NHE1  ||| S:707 E:712 ||| NNP
and  ||| S:712 E:716 ||| CC
3  ||| S:716 E:718 ||| CD
PPRE  ||| S:718 E:723 ||| NN
motifs  ||| S:723 E:730 ||| NNS
in  ||| S:730 E:733 ||| IN
MnSOD ||| S:733 E:738 ||| JJ
.  ||| S:738 E:740 ||| .
We  ||| S:740 E:743 ||| PRP
experimentally  ||| S:743 E:758 ||| RB
confirmed  ||| S:758 E:768 ||| VBD
the  ||| S:768 E:772 ||| DT
true  ||| S:772 E:777 ||| JJ
motifs  ||| S:777 E:784 ||| NNS
and  ||| S:784 E:788 ||| CC
their  ||| S:788 E:794 ||| PRP$
regulation  ||| S:794 E:805 ||| NN
by  ||| S:805 E:808 ||| IN
PPAR ||| S:808 E:812 ||| NNP
.  ||| S:812 E:814 ||| .
Our  ||| S:814 E:818 ||| PRP$
results  ||| S:818 E:826 ||| NNS
suggest  ||| S:826 E:834 ||| VBP
that  ||| S:834 E:839 ||| IN
both  ||| S:839 E:844 ||| DT
NHE1  ||| S:844 E:849 ||| NNP
and  ||| S:849 E:853 ||| CC
MnSOD  ||| S:853 E:859 ||| NNS
have  ||| S:859 E:864 ||| VBP
PPRE  ||| S:864 E:869 ||| JJ
binding  ||| S:869 E:877 ||| JJ
motif  ||| S:877 E:883 ||| NN
in  ||| S:883 E:886 ||| IN
their  ||| S:886 E:892 ||| PRP$
upstream ||| S:892 E:900 ||| JJ
/ ||| S:900 E:901 ||| CD
promoter  ||| S:901 E:910 ||| NN
region  ||| S:910 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
hence  ||| S:921 E:927 ||| RB
are  ||| S:927 E:931 ||| VBP
regulated  ||| S:931 E:941 ||| VBN
by  ||| S:941 E:944 ||| IN
PPAR  ||| S:944 E:949 ||| NNP
upon  ||| S:949 E:954 ||| IN
ligand  ||| S:954 E:961 ||| JJ
binding ||| S:961 E:968 ||| NN
.  ||| S:968 E:970 ||| .
